Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Dermatology Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Dermatology Other
    Phenytoin, Fosphenytoin May Increase Risk of Serious Skin Reactions in Asian Patients With HLA-B*1502 Allele - (DGNews)
    Swissmedic Approves Ceftobiprole Medocaril for Treatment of Complicated Skin Structure Infections - (DGNews)
    Subcutaneous Ecallantide Effective for Treatment of Acute Hereditary Angio-Oedema Episodes: Presented at ACAAI - (DGDispatch)
    Uremic Pruritus Impairs Key Aspects of Quality of Life in Hemodialysis Patients: Presented at ASN - (DGDispatch)
    New Method Estimates Radiation Skin Doses During CT-Guided Interventional Procedures - (DGNews)

    News archive

     Recent webcasts/CME - Dermatology Other
    • Moving Beyond Standard Therapy in Malignant Melanoma: Novel Agents and Combinations
    • Adjuvant Interferon Therapy Prolongs Relapse-Free Interval and Survival in Melanoma
    • Maintenance Debridement in the Treatment of Difficult-to-Heal Chronic Wounds
      Eradicating Lice: Myths and Facts
      Sunburn: The Summertime Blues

      Webcasts/CME archive

       Recent cases - Dermatology Other
        Painless Pink Papules with Central Porcelain-white Scars
        Dermatomyositis and Supraventricular Tachycardia
        Sweet Syndrome During Pregnancy
        Multiple Papillae on Labia Minoraa
        Sister Mary Joseph's Nodule: Three Case Reports

        Cases archive
          




        my personal edition > dermatology other > news
        divider

          E-Mail this DGNews to a colleague

        DGNews


        National Institute for Clinical Excellence Recommends Protopic (Tacrolimus) as Treatment for Moderate to Severe Atopic Eczema

        MUNICH, GERMANY -- August 26, 2004 -- In its final Guidance issued, the National Institute for Clinical Excellence (NICE) in the UK recommends tacrolimus ointment (Protopic®) as a second-line treatment of moderate to severe atopic dermatitis (AD [eczema]) in both adults and children aged 2 years and older. Treatment with Protopic® can be continued until complete clearance of the lesions and there are no restrictions on the total body surface area that can be treated with Protopic®1,2.

        AD affects 10-20% of children worldwide3 and topical corticosteroids form the mainstay of treatment. However, eczema control frequently cannot be achieved with conventional therapy4. The NICE Guidance recommends the use of Protopic® in patients where the eczema has not been controlled by topical corticosteroids, where there is a serious risk of adverse effects from further topical corticosteroid use, particularly irreversible skin atrophy.

        Protopic® has also recently received a change of licence in Europe and can now be prescribed by any physician who has experience of treating AD. This includes not only dermatologists, but also paediatricians and general practitioners (GPs). The change of licence was granted by the European Medicines Agency (EMEA) in response to the extensive safety data gathered following the use of Protopic® in over one million patients.

        Dr Stephen Kownacki from the Primary Care Dermatology Society in the UK said: "Most patients with atopic eczema are managed by their GP and the NICE recommendations support the important role that steroid-free therapies, such as Protopic, are now playing in the management of AD in primary care."

        The concurrent recommendation for Pimecrolimus (Elidel®) by NICE, limits its use to second-line treatment of moderate atopic eczema that has not been controlled by topical corticosteroids, where there is a serious risk of adverse effects from further topical corticosteroid use, particularly irreversible skin atrophy.. Furthermore, it specifies that Pimecrolimus is to be used only in children aged 2 to 16 years and only on the face and neck area. NICE have recommended that Pimecrolimus should not be used at all in adults or in mild and severe cases.

        Protopic® is proven to be more effective than a mild corticosteroid therapy in children5 and at least as effective as a potent corticosteroid1, 6, in adults. Protopic® offers adequate potency for disease control in moderate to severe patients failing on conventional therapy with no evidence of compromising patient safety.

        · Protopic® 0.03% is indicated for the treatment of moderate to severe atopic dermatitis in children (2 years of age and above) who failed to respond adequately to conventional therapies. Protopic® 0.1% and 0.03% ointment are indicated in the treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies.


        References:
        1. Protopic® 0.1% Ointment Summary of Product Characteristics
        2. Protopic® 0.03% Ointment Summary of Product Characteristics
        3. DYM Leung, "Atopic dermatitis", The Lancet, 2003; 361: 151-160
        4. Furue, M et al. British Journal of Dermatology 2003, 148: 128-133
        5. Reitamo S et al. Arch Dermatol 2002; 109: 539-546
        6. Reitamo S et al. J Allergy Clin Immunol, 2002; 109: 547-555


        SOURCE: ACUMED



        E-Mail this DGNews to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send